Boccardo F, Decensi A, Guarneri D, Martorana G, Giberti C, Giuliani L
Department of Clinical Oncology, National Cancer Institute, Genova, Italy.
Cancer Chemother Pharmacol. 1988;22(2):172-4. doi: 10.1007/BF00257317.
Twenty-two orchiectomized men with progressive stage D2 prostate cancer were treated with a 3-week cycle of estramustine phosphate (EMP: from day 3 to day 21) and androgen priming (from day 1 to day 4). A partial response according to the NPCP-USA criteria was shown in 4 of 20 evaluable patients. Median progression-free survival of all patients was 24 weeks (range, 4-48) and median survival, 42 weeks (range, 4-112). Although in two cases treatment had to be stopped due to a marked increase in bone pain, no life-threatening side effects were observed. The androgen sensitivity of tumors was supported by the occurrence of increase in prostatic phosphatase and in bone pain in most patients. In this group of patients, androgen priming did not seem to potentiate the effectiveness of EMP, our results being comparable to those previously reported using EMP alone.
22名患有进展期D2前列腺癌的去势男性接受了为期3周的磷酸雌莫司汀（EMP：从第3天至第21天）和雄激素启动（从第1天至第4天）治疗。根据美国NPCP标准，20例可评估患者中有4例出现部分缓解。所有患者的无进展生存期中位数为24周（范围4 - 48周），总生存期中位数为42周（范围4 - 112周）。尽管有2例因骨痛明显加重而不得不停止治疗，但未观察到危及生命的副作用。大多数患者前列腺磷酸酶升高和骨痛的出现支持了肿瘤的雄激素敏感性。在这组患者中，雄激素启动似乎并未增强EMP的疗效，我们的结果与之前单独使用EMP的报道相当。
